<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In the course of <z:hpo ids='HP_0001635'>heart failure</z:hpo>, plasmatic levels of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> <z:mp ids='MP_0001651'>Necrosis</z:mp> Factor-alpha (TNF-alpha) are high and are related to prognosis and mortality </plain></SENT>
<SENT sid="1" pm="."><plain>Infliximab, a recombinant chimeric antibody anti-TNF-alpha, was used in <z:hpo ids='HP_0001635'>heart failure</z:hpo> with disappointing results, similar to those obtained with other biological drugs.The aim of this study was the echocardiographic evaluation of infliximab infusion in nine patients without cardiac pathologies </plain></SENT>
<SENT sid="2" pm="."><plain>The findings demonstrate a reduction of sistolic function and a modification of diastolic function after infliximab infusion in patients without <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">cardiopathy</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>This study confirms the protective role played by TNFalpha on the myocardium, as suggested by previous experimental studies </plain></SENT>
</text></document>